top of page

About CNS & its Mission 

About CNS
1-s2.0-S0306987715002789-gr1_lrg.jpg
Image-1.jpg
Elsevier Book Cover.png

The Center for Neurologic Study, a nonprofit 501c3 corporation, is a leader in an area now referred to as Translational Medicine. Our most recent success is the approval of Qalsody/Tofersen for the treatment of the SOD1 familial variant of ALS. This is considered a medical milestone in the history of this disorder. Prior to this, our director and colleagues were awarded the international Healey Prize for their ALS antisense drug discovery efforts. Further, we are pleased to announce the publication of Neurotherapeutics in the Era of Translational Medicine, which Dr. Smith co-edited with Clive Svendsen and Brian Kaspar (see publications). 

 

The seminal discovery of DMQ at CNS resulted in the development of Nuedexta. The drug, ultimately formulated by Avanir Pharmaceuticals Corporation, was approved by FDA for the treatment of labile emotionality that occurs in association with numerous neurological disorders. Recently, Nuedexta was demonstrated to enhance speech and swallowing in patients with ALS. The results were published in the Journal of Neurotherapeutics (see publications). To our knowledge, this placebo-controlled trial is the first to demonstrate the enhancement of any function in this disease. The study was funded by an award to Dr. Smith (ALS Association) who conceived and managed the study as principal investigator.

 

For those who have followed CNS over the years, we are pleased to announce a new direction for the foundation: the establishment of an angel investing fund. The purpose of the fund is to invest in seed stage preclinical drug, biomarker, and device development in the area of neurodegenerative disorders. Since its inception, we have provided funding for 3 companies. 

 

In collaboration with Amprion Inc., we have identified a self-replicating protein in the spinal fluid of approximately fifteen percent of ALS patients. While this could be an incidental finding, this subgroup of patients may represent a unique treatment opportunity. The results of this research will be published in the European Journal of Neurology early in 2024. 

 

Our success is due in part to the support we have received from individuals, corporations and foundations. If you’ve come upon us, consider making a donation, if not to us, make a donation to the cause that concerns you.​

bottom of page